New Zealand markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
109.14+0.38 (+0.35%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close108.76
Bid0.00 x 2200
Ask0.00 x 900
Day's range108.31 - 109.22
52-week range79.11 - 121.53
Avg. volume7,141,750
Market cap192.87B
Beta (5Y monthly)0.83
PE ratio (TTM)29.43
EPS (TTM)3.71
Earnings date29 Oct 2021
Forward dividend & yield5.20 (4.76%)
Ex-dividend date14 Oct 2021
1y target est127.01
  • Zacks

    AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

    AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

    J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

  • Motley Fool

    3 Leading Healthcare Stocks to Buy in 2021 and Beyond

    Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. ResMed is already an industry leader in sleep apnea therapies, an area that's expected to grow as our population ages. Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity that protects its long-term outlook.